Church & Dwight Waves History Flag Behind Boosting Arm & Hammer Brand Sales
“The US is celebrating its 250-year anniversary. Church & Dwight's 180 years,” says CEO Richard Dierker. Arm & Hammer brand awareness is in the “mid- to high-90s” and “rivals almost any other brand that you know.”
HBW Insight - June 2, 2026

Travere Adds Kidney Disease Building Block With Everest Deal
The company is adding the oral BTK inhibitor civorebrutinib to its portfolio for the development of rare kidney diseases, paying Everest $112.5m upfront.
Scrip - June 2, 2026

Medtech Sweden: Inside Gothenburg’s GoCo, A House And City Built For Innovation
This article, the second drawn from a media event hosted by the City of Gothenburg, spotlights a visit to GoCo House Health Innovation City, a life-science district where over 100 companies, research institutions and academic partners share labs and offices adjacent to AstraZeneca’s R&D hub.
Medtech Insight - June 2, 2026

Podcast: Jeremy Levin’s Call to Action to Save American Biotech
Jeremy Levin, an industry veteran and author of a new book, argues that biotech must defend scientific integrity, attract long-term capital, and rebuild public trust. Otherwise, it risks ceding America's innovation primacy to global competitors.
In Vivo - June 2, 2026

Titans Of Pharma: Big Pharma CEO Pay Rebounds 19% In 2025
Big pharma CEO pay rebounded in 2025, with mean compensation up 19% to $23.0m. Eli Lilly further extended David Ricks's lead as best-compensated CEO over AbbVie's Robert Michael and J&J's Joaquin Duato.
Scrip - June 2, 2026

The AI Reading 1,000-Page Cancer Records Before Your Doctor Does
Triomics has raised $22m and deployed its clinical trial matching platform at four of the country’s top cancer centers. Its CEO says the hardest problem wasn’t the technology – it was convincing physicians the machine could reason.
Medtech Insight - June 2, 2026

ASCO: GSK’s Plans To Unseat Gleevec and Sutent With Velzatinib Advance In GIST
The KIT inhibitor impresses with early results in the firm's bid to become a leader in gastrointestinal stromal tumors.
Scrip - June 2, 2026

Hikma Invests $267m In Ohio Facility Expansion
Hikma has revealed an investment of more than a quarter of a billion dollars in its Bedford and Columbus facilities in Ohio, delivering on a commitment it made last year to spend a full billion over the next five years to further expand its US manufacturing base.
Generics Bulletin - June 2, 2026

From “Drag” to Driver: Glenmark Bets Big On US Business Take Off
Glenmark's “aggressive” FY27 revenue target counts on traction across several fronts including plans to launch in-licensed oncology drugs from Chinese partners, strong growth for Ryaltris and a resurgence of the US business.
Scrip - June 2, 2026

Stock Watch: Why Merck & Co. Was An Outlier In Earnings Season
Merck & Co.’s Q1 earnings beat expectations but its stock fell nearly 2%, making it an outlier on a day when the pharma index rose by 4%. Keytruda concentration and a stumbling COPD drug acquisition weighed on sentiment even as vaccine franchise green shoots emerged.
Scrip - June 2, 2026

Abivax Targets FDA Filing After Positive Phase III UC Data But Malignancy Questions Hit Shares
Attention is now shifting to how regulators, physicians and investors interpret malignancy findings that overshadowed an otherwise successful readout.
Scrip - June 2, 2026

ASCO: Data Presentations (And An Approval) Illustrate Competitive TROP2 Race
Gilead Sciences, Daiichi Sankyo/AstraZeneca and Merck/Kelun all showcased their TROP2-directed antibody-drug conjugates at the ASCO meeting.
Scrip - June 2, 2026

Outlook Eyes Rapid FDA Approval For Ophthalmic Bevacizumab With Refiled BLA
Outlook Therapeutics has once again resubmitted its filing for its bevacizumab-based Lytenava ophthalmology treatment to the FDA, following the favorable outcome of a recent dispute resolution process. A PDUFA date and decision are expected within 60 days.
Generics Bulletin - June 2, 2026

Apotex Aims For Over C$1bn As It Launches IPO
Apotex has revealed financial details of its recently-announced IPO, with the Canadian generics and biosimilars giant seeking proceeds of more than C$1bn in a move that would value the firm at more than C$5bn.
Generics Bulletin - June 2, 2026

Celltrion Uses Canada To Crack Open Cosentyx Market
Celltrion’s Canadian filing for CT-P55 looks to give it an early route into North America’s major Cosentyx biosimilar opportunity, as Western rivals remain absent and Asian developers define the field.
Generics Bulletin - June 2, 2026

PCOS Renamed PMOS: What The Reclassification Means For Drug Development And Market Access
The global consensus reclassifying polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) is opening new fronts in drug development, at-home diagnostics, and chronic disease management.
In Vivo - June 2, 2026

GRAIL’s Galleri Cleared Secondary Bars At ASCO, But Primary Endpoint Miss Remains
Galleri met multiple secondary endpoints at ASCO 2026. Still, the NHS-Galleri trial's failure to hit its primary combined Stage III/IV endpoint leaves FDA reviewers and payers weighing compelling secondary data against a key statistical shortfall.
Medtech Insight - June 2, 2026

Agios Secures Oscotec’s Next Generation SYK Inhibitor In $665m Deal
Agreement expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026

ASCO: CStone’s First-In-Class Trispecific Shows Strong Activity In 1L NSCLC
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026